300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Retail
Cryptocurrency
Social Impact
SaaS
Film
Photography
Restaurants
Email
Payments
Energy
CleanTech
Organic Food
Marketplace
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Video Games
Big Data
Medical Device
Mobile
Automotive
Sports
Wellness
Legal
Education
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Venture Capital
Medical
Recruiting
Web3
Cannabis
Fashion
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Social
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Beauty
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Infrastructure
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Kyrgyzstan
LATAM
Africa
Oceania
Poland
Oman
Puerto Rico
Cameroon
Guernsey
Sudan
Andorra
Colombia
China
Armenia
Czech Republic
Costa Rica
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Canada
Indonesia
United Kingdom
Middle East
Dominican Republic
Asia
Bermuda
Albania
Spain
Argentina
Angola
Europe
Cyprus
Bangladesh
Qatar
Belgium
Barbados
Jordan
Austria
Azerbaijan
Ethiopia
Bulgaria
Ecuador
Bahamas
Bolivia
Algeria
Belize
Finland
Faroe Islands
Estonia
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Jersey
Bahrain
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Peru
Mongolia
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
New Leaf Venture Partners, VC Fund

New Leaf Venture Partners

VC Fund

New York, United States

New Leaf Venture Partners is a venture capital firm that invests primarily in healthcare technology. The company typically focuses on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.The New Leaf Ventures (NLV) team has been built over a decade, originating within Sprout Group, theventure capital affiliate of Credit Suisse First Boston. Sprout Group was formed in 1969 and has historically been one of the leading venture capital firms in the country. The team started to invest in healthcare technology in 1993 and since then, has become a leading venture investor in that sector. In 2005, the entire healthcare technology team of Sprout spun out into NLV.

Total investments:
156
Last investment:
Lead investor:
23%
Last fund:

Last updated:

Industries New Leaf Venture Partners invests in

Health CareBiotechnologyMedicalPharmaceuticalTherapeutics

Stages New Leaf Venture Partners invests in

Series BSeries CSeries AFunding RoundSeries D

Countries New Leaf Venture Partners invests in

United StatesUnited KingdomCanadaIsraelSweden

Round sizes

Series A $10M–$60MSeries B $10M–$75MSeries C $20M–$101M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$10M–$60M
Series B
$10M–$75M
Series C
$20M–$101M

Investment Focus

Industry

  • Health Care 68 (44%)
  • Biotechnology 59 (38%)
  • Medical 33 (21%)
  • Pharmaceutical 23 (15%)
  • Therapeutics 22 (14%)
See all 55 industries →

Stage

  • Series B 35 (22%)
  • Series C 29 (19%)
  • Series A 22 (14%)
  • Funding Round 14 (9%)
  • Series D 11 (7%)
See all 14 stages →

Country

  • United States 79 (51%)
  • United Kingdom 4 (3%)
  • Canada 2 (1%)
  • Israel 1 (1%)
  • Sweden 1 (1%)
See all 9 countries →

Team

NameTitleInvestmentsLinksEmail
Craig Slutzkin
Craig Slutzkin CFO & COO
CFO & COO Total investments: 0
Find email
James Niedel
James Niedel Managing Director
Managing Director Total investments: 8
Find email
Liam Ratcliffe
Liam Ratcliffe Managing Director
Managing Director Total investments: 17
Find email
Ronald Hunt
Ronald Hunt Managing Director
Managing Director Total investments: 5
Find email
Vijay Lathi
Vijay Lathi Managing Director
Managing Director Total investments: 26
Find email

Investments

CompanyDescriptionRoundLinks
BrightInsight BrightInsight
BrightInsight provides a digital health platform for bio-pharma and med-tech. Its IoT platform is built under a quality management system to support and optimize regulated drugs, devices, and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement. BrightInsight was foundedin 2017 and is headquartered in San Jose, California. $13M / Venture - Series Unknown / Jan 20, 2026
Electra Therapeutics Electra Therapeutics
Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases. $183M / Series C / Oct 22, 2025
Star Therapeutics Star Therapeutics
Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients. $125M / Series D / Sep 30, 2025
Abcuro Abcuro
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. $200M / Series C / Feb 12, 2025
Kalderos Kalderos
Kalderos is the creator of a drug discount management solution. It provides a SaaS-based drug discount management solution, which identifies, checks, and resolves non-compliance. Using models and machine learning processes, Kalderos detects inconsistencies overlooked by current methods, providing material benefits by eliminating waste. It wasfounded in 2016 and is headquartered in Chicago, Illinois. $26.4M / Venture - Series Unknown / Jan 03, 2025
Sunbird Bio Sunbird Bio
Sunbird Bio is a diagnostics platform developer that aims to give molecular diagnostics with faster outcomes. Sunbird Bio was founded by Huilin Shao. $14M / Venture - Series Unknown / Oct 16, 2024
Windup Minds Windup Minds
Windup Minds is a game studio focused on creating VR and MR virtual pet experiences. The company runs a gaming studio that aims to bring virtual pet games to market. Pre-Seed / Oct 15, 2024
Truveris Truveris
Truveris brings transparency to the prescription drug ecosystem through data-driven innovations. Truveris’ platform offers customers – from the individual patient to employers, retailers, pharmacy benefits stakeholders, and manufacturers – the data and insights they need to effectively and efficiently manage rising costs and market accesschallenges.Based in Manhattan, Truveris is backed by Canaan Partners, New Leaf Venture Partners, Tribeca Venture Partners, New Atlantic Ventures and First Round Capital. $15M / Series E / May 14, 2024
Qlaris Bio Qlaris Bio
Qlaris Bio focuses on developing novel and innovative therapies for serious and debilitating ophthalmic diseases. Qlaris Bio is a spinout company of Qrativ, a biotechnology incubator formed as a joint venture between Mayo Clinic and inference, a pharmaceutical-focused artificial intelligence company. Its lead program is QLS-101, a novel compoundinvented at Mayo Clinic and the University of Minnesota. QLS-101, with its unique and first-in-class mechanism of action, may potentially serve as an efficacious treatment for high unmet need conditions related to disturbances in intraocular pressure, including a sight-threatening and progressive Pediatric Rare Disease for which effective therapies remain elusive and limited.Qlaris Bio was founded in 2019 and is headquartered in Cambridge, Massachusetts. $24M / Series B / Apr 22, 2024
Flosonics Flosonics
Flosonics is a medical device company that focuses on developing non-invasive sensors to improve the management of critically ill patients. Flosonics's flagship smart-bandage product, the FloPatch, addresses unmet clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance,emergency department, operating room, and intensive care unit. $20M / Series C / Mar 19, 2024
See all 156 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Retail
Cryptocurrency
Social Impact
SaaS
Film
Photography
Restaurants
Email
Payments
Energy
CleanTech
Organic Food
Marketplace
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Video Games
Big Data
Medical Device
Mobile
Automotive
Sports
Wellness
Legal
Education
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Venture Capital
Medical
Recruiting
Web3
Cannabis
Fashion
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Social
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Beauty
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Infrastructure
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Kyrgyzstan
LATAM
Africa
Oceania
Poland
Oman
Puerto Rico
Cameroon
Guernsey
Sudan
Andorra
Colombia
China
Armenia
Czech Republic
Costa Rica
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Canada
Indonesia
United Kingdom
Middle East
Dominican Republic
Asia
Bermuda
Albania
Spain
Argentina
Angola
Europe
Cyprus
Bangladesh
Qatar
Belgium
Barbados
Jordan
Austria
Azerbaijan
Ethiopia
Bulgaria
Ecuador
Bahamas
Bolivia
Algeria
Belize
Finland
Faroe Islands
Estonia
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Jersey
Bahrain
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Peru
Mongolia
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does New Leaf Venture Partners invest in?

New Leaf Venture Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 156 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is New Leaf Venture Partners's check size?

New Leaf Venture Partners typically joins rounds of $10M–$60M at Series A, $10M–$75M at Series B and $20M–$101M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds New Leaf Venture Partners participates in.

How do I contact New Leaf Venture Partners?

Public channels for New Leaf Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at New Leaf Venture Partners?

The team at New Leaf Venture Partners includes Craig Slutzkin (CFO & COO), James Niedel (Managing Director) and Liam Ratcliffe (Managing Director). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
New Leaf Venture Partners New Leaf Venture Partners Find emails